Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Are The Gains In These Hot Monday Stocks Sustainable?

It’s a good Monday for investors of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV), Amicus Therapeutics, Inc. (NASDAQ:FOLD), and Oasis Petroleum Inc. (NYSE:OAS), as all three stocks have made significant jumps today. We’ll take a look at the reason why these stocks are being propelled higher and whether elite money managers think the gains are sustainable or not.

arrow, up, rising

Why are we interested in the 13F filings of a select group of hedge funds? We use these filings to determine the top 15 small-cap stocks held by these elite funds based on 16 years of research that showed their top small-cap picks are much more profitable than both their large-cap stocks and the broader market as a whole. These small-cap stocks beat the S&P 500 Total Return Index by an average of nearly one percentage point per month in our backtests, which were conducted over the period of 1999 to 2012. Moreover, since the beginning of forward testing from August 2012, the strategy worked just as our research predicted, outperforming the market every year and returning 118% over the last 36 months, which is more than 60 percentage points higher than the returns of the S&P 500 ETF (SPY) (see more details).

ContraVir Pharmaceuticals Inc (NASDAQ:CTRV)’s shares are up by a staggering 105.69% after the firm announced that its preliminary data for CMX157, its lipid prodrug of tenofovir, has shown that the treatment is 60-fold more effective than Gilead Sciences, Inc. (NASDAQ:GILD)’s Viread (tenofovir disoproxil fumarate) based on in vitro studies targeting the hepatitis B virus (HBV). The significant difference in effectiveness points to a considerable increase in safety and reduction of side effects compared to Viread, the firm notes. ContraVir said that since the lipid-conjugate design of CMX157 differentiates the drug from Viread, they plan to file an investigational new drug application for CMX157 as a treatment for HBV before the year ends. The firm also announced that its Phase 2 study for the drug for treating hepatitis B will start in 2016. It should be noted, nonetheless, that none of the more than 700 investors we track reported owning shares of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) by the end of the second quarter.

Follow Hepion Pharmaceuticals Inc. (NASDAQ:HEPA)
Trade (NASDAQ:HEPA) Now!

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.